AnteoTech Scales Ultranode™ 70 Tenfold, Hits 1,000 Cycles Milestone

Battery Technology Breakthroughs

AnteoTech Ltd has delivered a robust quarterly update for the period ending 31 December 2025, underscoring its dual focus on advanced battery technologies and life sciences diagnostics. The company’s Advanced Battery Technologies (ABT) division achieved a significant milestone with a 10-fold manufacturing scale-up of its Ultranode™ 70 anode material, now undergoing commercial form factor cell evaluations with Wyon AG. This scale-up demonstrates the company’s ability to produce at volumes relevant for commercial applications, a critical step toward market adoption.

Further bolstering its battery credentials, AnteoTech’s Ultranode™ X product surpassed a key performance benchmark by achieving over 1,000 full charge-discharge cycles while retaining 80% capacity. This milestone is particularly notable as it meets a widely referenced threshold for electric vehicle batteries, positioning AnteoTech competitively in a market hungry for durable, high-performance silicon anode materials.

Strategic US Partnership and Market Expansion

A pivotal development was the execution of a Joint Development and Sales Agreement with US-based Black Diamond Structures (BDS). This partnership combines AnteoTech’s Anteo X™ cross-linking additive with BDS’s Molecular Rebar™ carbon nanotube dispersion technology to create a novel battery product. Early customer trials are slated to commence in February 2026, setting the stage for anticipated sales growth in the US market during the latter half of the fiscal year.

AnteoTech is also negotiating joint development agreements with battery manufacturers supplying drone makers, particularly targeting the US defence sector. This diversification into high-growth, specialised battery applications reflects a strategic approach to capturing emerging market segments.

Life Sciences Momentum

On the life sciences front, the company secured a US$185,000 order from the Serum Institute of India (SII), a key partner under a five-year supply agreement. This order, fulfilled in early January 2026, underscores growing traction for AnteoBind™, the company’s proprietary activation chemistry used in diagnostic assays.

AnteoTech is advancing product development in the lucrative ELISA and CLIA immunoassay markets, which collectively represent billions in global market value. The company’s AnteoBind™ NXT product demonstrated significant cost and performance advantages over existing chemistries, including up to six times lower antibody usage and reduced non-specific binding. These benefits could translate into meaningful cost savings and improved assay reliability for diagnostic manufacturers.

Financial Position and Corporate Updates

Financially, AnteoTech strengthened its runway with a successful capital raise of A$3.5 million in January 2026, completed at a share price of 1.55 cents. This infusion boosts the company’s pro-forma cash balance to approximately A$4.9 million, providing a solid foundation to support sales growth and strategic partnership development throughout 2026.

Corporate changes included the resignation of Chief Financial Officer Andrew Cook, with Scott Waddell appointed as interim CFO. The company is actively recruiting for a permanent replacement, signalling a focus on maintaining financial stewardship during this growth phase.

Looking Ahead

AnteoTech’s immediate priorities include converting ongoing customer trials into sales, particularly for new products targeting ELISA, CLIA, and battery separator markets. The company plans to leverage upcoming industry conferences in South Korea and the US to deepen customer engagement and accelerate commercialisation efforts.

With multiple promising technologies advancing through development and validation, AnteoTech is positioning itself at the intersection of two dynamic sectors. The company’s ability to scale manufacturing, secure strategic partnerships, and strengthen its financial base will be critical to translating innovation into sustainable revenue growth.